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Lysyl-tRNA synthetase produces diadenosine 
tetraphosphate to curb STING-dependent inflammation
J. Guerra1, A.-L. Valadao1, D. Vlachakis2, K. Polak1, I. K. Vila1, C. Taffoni1, T. Prabakaran3, 
A. S. Marriott4, R. Kaczmarek5, A. Houel6, B. Auzemery1, S. Déjardin1, P. Boudinot6, B. Nawrot5, 
N. J. Jones7, S. R. Paludan3, S. Kossida8, C. Langevin6*, N. Laguette1†
Inflammation is an essential part of immunity against pathogens and tumors but can promote disease if not tightly 
regulated. Self and non-self-nucleic acids can trigger inflammation, through recognition by the cyclic GMP-AMP 
(cGAMP) synthetase (cGAS) and subsequent activation of the stimulator of interferon genes (STING) protein. Here, 
we show that RNA:DNA hybrids can be detected by cGAS and that the Lysyl-tRNA synthetase (LysRS) inhibits STING 
activation through two complementary mechanisms. First, LysRS interacts with RNA:DNA hybrids, delaying recogni-
tion by cGAS and impeding cGAMP production. Second, RNA:DNA hybrids stimulate LysRS-dependent production 
of diadenosine tetraphosphate (Ap4A) that in turn attenuates STING-dependent signaling. We propose a model 
whereby these mechanisms cooperate to buffer STING activation. Consequently, modulation of the LysRS-Ap4A axis 
in vitro or in vivo interferes with inflammatory responses. Thus, altogether, we establish LysRS and Ap4A as pharma-
cological targets to control STING signaling and treat inflammatory diseases.
INTRODUCTION
Dinucleotides are bioactive molecules for which a signaling role in 
mammalian cells has emerged in recent years. In particular, cyclic 
dinucleotides, such as cyclic guanosine monophosphate–adenosine 
monophosphate (cGAMP), have been described as activators of the 
inflammatory response (1). In the presence of self- or non-self–nucleic 
acid species, the cyclic GMP-AMP synthase (cGAS) DNA sensor 
produces cGAMP (2), activating inflammatory responses (3). A 
pivotal step in the mounting of this response to immune-stimulatory 
nucleic acids is the interaction of cGAMP with the stimulator of 
interferon genes (STING) (4, 5), which leads to the recruitment of the 
tank binding kinase 1 (TBK1) and transcription factors, including 
interferon response factor 3 (IRF3) (6). The assembly of this STING 
signalosome leads to the phosphorylation of IRF3 that translocates 
into the nucleus to orchestrate the transcription of a set of genes 
that includes proinflammatory cytokines and type I interferon 
(IFN) (6). Dysregulation of the cGAS-STING pathway fuels several 
inflammatory human pathologies, including autoimmune, auto-
inflammatory, and malignant disorders (7). The development of 
means to act on the cGAS-STING signaling pathway is therefore 
paramount to current therapies aiming to curb disease-associated 
inflammation (8). Small molecules that modulate cGAS-STING 
pathway activation have been identified (9), opening novel investi-
gation avenues. Yet, in certain pathologies, what determines the 
outcome of STING activation or inhibition remains unknown (10). 
This underscores the pressing need for a better understanding of 
the mechanisms regulating the cGAS-STING pathway in different 
cellular contexts.
Cytosolic double-stranded DNA (dsDNA) species are the main 
activators of the cGAS-STING pathway, but recently, RNA:DNA 
hybrids have also been described as possible ligands for cGAS. However, 
the molecular mechanisms involved in their recognition and in the 
regulation of ensuing inflammatory cytokines production are poorly 
described. RNA:DNA hybrids can arise as by-products of several 
physiological processes, including DNA replication, immunoglobulin 
class switching and hypermutation, or double-strand DNA break 
repair (11). Endogenous and exogenous reverse transcriptases also 
contribute to generating RNA:DNA hybrids (12, 13). Regardless of 
their origin, these moieties can threaten cellular integrity, by promoting 
unwanted triggering of inflammatory responses (12–14). However, 
while RNA:DNA hybrids can stimulate cGAS-dependent cGAMP 
production in vitro (14), it is still unknown whether such inter-
action can occur in cells.
To identify proteins involved in the detection of RNA:DNA 
hybrids and in the regulation of associated inflammatory re-
sponses, we used a biochemistry approach. We thereby identified 
the Lysyl tRNA synthetase (LysRS), which is a component of the 
cytosolic multi- tRNA synthetase complex (MSC), as a direct 
binding partner of RNA:DNA hybrids. While LysRS plays major 
roles in translation through aminoacylation of the cognate tRNA, 
noncanonical functions have been described (15, 16), including 
regulation of immune response (17–19). This prompted us to 
investigate the role of LysRS in detection and regulation of RNA:DNA 
hybrid–induced inflammatory responses. We thus demonstrate 
that RNA:DNA hybrids can be detected by cGAS and that LysRS 
can regulate subsequent STING activation through two comple-
mentary mechanisms. On one hand, LysRS interacts with cytosolic 
RNA:DNA hybrids, delaying recognition by cGAS. On the other 
hand, stimulation of cells with RNA:DNA hybrids leads to 
LysRS- dependent diadenosine tetraphosphate (Ap4A) production. 
This second messenger can associate with STING, delaying its 
activation. We therefore show that the LysRS-Ap4A pathway 
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contributes to regulate nucleic acid-dependent cGAS-STING 
activation.
RESULTS
The MSC interacts with RNA:DNA hybrids
To identify RNA-DNA interacting proteins, we used a blunt synthetic 
40-nt-long RNA:DNA hybrid bearing a 5′ biotin (BRNA:DNA; 
fig. S1A). We first verified the stability of synthetic RNA:DNA hybrids 
by immunofluorescence (fig. S1B) in mouse embryonic fibroblasts 
(MEFs), together with their ability to elicit a proinflammatory response 
in MEF, MEF knocked out for Sting (MEFSting−/−) or cGas (MEFcGas−/−). 
The latter was assessed by measuring Ifn mRNA levels by real-time 
quantitative polymerase chain reaction (RT-qPCR) (Fig. 1A) and IRF3 
phosphorylation (pIRF3) by Western blot (WB; Fig. 1B). As expected 
(14), synthetic RNA:DNA hybrids induced IFN production in a 
cGAS-STING–dependent manner. We next performed in vitro 
pull-down assays by incubating cytosolic extracts (S100) from 
HeLa-S3 cells (fig. S1C) with BRNA:DNA hybrids before pull-down 
using streptavidin-affinity magnetic beads and elution (Fig. 1C, left). 
Biotinylated single-stranded RNA (ssBRNA) was included as a control. 
Eluted material was resolved by SDS–polyacrylamide gel electropho-
resis (PAGE) and either silver-stained (Fig. 1C, right) or processed 
by mass spectrometry. Protein enrichment data revealed substantial 
interaction with all members of the MSC that is a central actor in 
protein synthesis, composed by eight tRNA synthetases: GluRSEPRS, 
IleRSIARS, LeuRSLARS, GlnRSQARS, MetRSMARS, ArgRSRARS, LysRSKARS, 
AspRSDARS, and three scaffold proteins: p43AIMP1, p38AIMP2, and p18AIMP3 
(fig. S1D) (20). Using WB, we confirmed that proteins of the MSC 
interact with BRNA:DNA hybrids, but not with ssBRNA or ssBDNA, 
in vitro (Fig. 1D). We recapitulated the specific interaction of the 
MSC with RNA:DNA hybrids in human (Fig. 1E) and murine cells 
(Fig. 1F) upon transfection of BRNA:DNA hybrids and streptavidin 
pull-down. We therefore show that the MSC is recruited to RNA:DNA 
hybrids both in vitro and in cells.
The Lyslyl tRNA synthetase interacts directly  
with RNA:DNA hybrids
We next investigated which member of the MSC is responsible for 
its interaction with RNA:DNA hybrids. Three members of the MSC 
complex, namely, LysRS, AspRS, and p43, comprise oligonucleotide/
oligosaccharide binding (OB)–fold domains that are predicted to bind 
nucleic acids (21). Thus, we tested whether these proteins can direct-
ly interact with RNA:DNA hybrids using recombinant glutathione 
S-transferase (GST)–tagged proteins (fig. S2A). GST was used as negative 
control. We incubated purified proteins with BRNA:DNA hybrids 
before pull-down using streptavidin affinity beads and analysis by WB 
using an anti-GST antibody. We thereby show that LysRS displays 
strong binding to RNA:DNA hybrids (Fig. 2A) and that this interac-
tion is Ribonuclease H (RNaseH)–sensitive (Fig. 2B). We further char-
acterized the binding of LysRS to RNA:DNA hybrids, using full-length 
LysRS or LysRS constructs harboring either a N-terminal deletion 
of the putative OB-fold nucleic acid binding domain (LysRS∆N) 
or a C-terminal deletion of the catalytic aminoacyl transferase domain 
(LysRS∆C) (22). Recombinant GST-LysRS, GST- LysRS∆N, GST- 
LysRS∆C, and GST (fig. S2B) were used in in vitro pull-down ex-
periments using BRNA:DNA hybrids immobilized on streptavidin 
affinity beads. This showed that LysRS interacts with RNA:DNA hybrids 
through its N-terminal domain (Fig. 2C). This binding is sensitive 
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Fig. 1. MSC is recruited to RNA:DNA hybrids. (A) Mean (±SEM), Ifn mRNA levels 
in WT-MEF, MEFSting−/−, and MEFcGAS−/− transfected or not with RNA:DNA hybrids 
(R:D); n = 8. t test, ****P < 0.0001. (B) WB analysis of whole-cell extracts of cells treated 
as in (A). Membranes were probed with the indicated antibodies. (C) Left: Experi-
mental scheme. MS, mass spectrometry; ssBRNA, biotinylated ssRNA; BR:D, 
biotinylated RNA:DNA hybrids. Right: Silver staining of samples obtained following 
the experimental scheme. Numbers indicate molecular weight (MW) in kDa. (D) WB 
analysis of pull-down performed as in (C), except that biotinylated ssDNA (ssBDNA) 
was included as a control. (E) HeLa cells were transfected or not with biotinylated 
BR:D, ssBRNA, or biotinylated dsDNA (BD:D) before whole-cell extract preparation 
and pull-down using streptavidin affinity beads. Input and eluates were analyzed 
by WB using the indicated antibodies. (F) As in (E), except that WT-MEF were trans-
fected with BR:D before pull-down. Input and eluates were analyzed by WB using 
the indicated antibodies. All immunoblots show representative experiments.
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to RNaseH treatment (Fig. 2D). We additionally confirmed that 
murine LysRS (fig. S2B) binds RNA:DNA hybrids (fig. S2C) and 
that this binding is RNaseH sensitive (fig. S2D) as observed for hu-
man LysRS (Fig. 2, A to C). Thus, our in vitro experiments shown that 
LysRS can directly bind RNA:DNA hybrids.
Our in vitro binding data further suggest that LysRS may be the 
key to the recruitment of MSC proteins to RNA:DNA hybrids. To 
test this, we first FLAG-purified overexpressed FLAG-hemagglutinin 
(HA)–tagged LysRS (F/HA-LysRS) from the cytosolic fraction of 
HeLa cells. Eluted material was used as input for pull-down using 
streptavidin-immobilized BRNA:DNA hybrids (Fig. 2E, left). WB 
analysis using antibodies targeting proteins of the MSC complex 
revealed that all tested members coprecipitated with RNA:DNA hybrids 
(Fig. 2E, right). We confirmed the specificity of this interaction by 
RNaseH treatment of the BRNA:DNA hybrids before binding to the 
streptavidin affinity beads (Fig. 2E, right). We next knocked down 
LysRS in cells before pull-down assays using BRNA:DNA hybrids. 
This showed that decreased levels of LysRS (Fig. 2F, compare lanes 
1 and 2) are accompanied by decreased association of other tested 
components of the MSC (Fig. 2F, compare lanes 4 and 6). This indi-
cates that the presence of LysRS is the key to the recruitment of the 
MSC to RNA:DNA hybrids in cells. Last, we questioned whether 
LysRS interacts with endogenous RNA:DNA hybrids. To this aim, 
we adapted the S9.6 antibody–based DNA:RNA hybrid immuno-
precipitation protocol [adapted from (13)]. Using the HeLa cell line 
that presents endogenous RNA:DNA hybrids (fig. S2E), we confirmed 
that endogenous RNA:DNA hybrids immunoprecipitated LysRS 
(Fig. 2G). This was further confirmed by experiments where endogenous 
GlnRS was immunopurified, before assessment of the presence of other 
components of the MSC and extraction of GlnRS-associated DNA 
(fig. S2F). WB analysis of the eluates confirmed the presence of LyRS 
(fig. S2F, middle), and quantitative PCR analysis showed an enrich-
ment of sequences belonging to the high-copy satellite II region of 
the human genome (fig. S2F, right) that is reported to produce RNA:DNA 
hybrids (23). Thus, together, our data show that within the MSC 
complex LysRS is the main mediator of the interaction with RNA:DNA 
hybrids.
The Lysyl tRNA synthetase inhibits RNA:DNA  
hybrid-induced IFN production
While the main reported function of LysRS within the MSC complex 
is to aminoacylate its cognate tRNA, there are reports of additional 
noncanonical functions, including negative regulation of immune 
responses (15, 16). Thus, we interrogated whether LysRS can modulate 
RNA:DNA hybrid–associated inflammation. To this aim, we trans-
duced WT-MEF with a LysRS targeting short hairpin RNA (shRNA) 
(shLysRS) or with a control Luciferase targeting shRNA (shLuc), 
before transfection or not with RNA:DNA hybrids for 3, 6, and 
12 hours. Cells were harvested and analyzed for Ifn mRNA levels 
by RT-qPCR (Fig. 3A), as well as by WB against phosphorylated 
IRF3 (pIRF3) (Fig. 3B). This showed that the absence of LysRS leads 
to up-regulated basal Ifn mRNA levels, which are further increased 
upon transfection of RNA:DNA hybrids. The kinetics of Ifn ex-
pression were faster in LysRS–knocked-down cells, suggesting that 
LysRS delays activation of the IFN response. These results were con-
firmed using the three prime repair exonuclease 1 (Trex1)–deficient 
MEF (MEFTrex1−/−), which is a well-characterized model of chronic 
inflammation that presents high levels of RNA:DNA hybrids together 
with elevated STING-dependent Ifn and interferon stimulated genes 
(ISGs) mRNA levels (fig. S3, A and B) (24). Following knockdown 
of LysRS in MEFTrex1−/−, we observed increased Ifn mRNA levels 
(Fig. 3C and fig. S3C) and increased levels of pIRF3 both at steady 
state and upon RNA:DNA hybrid stimulation (Fig. 3D and fig. S3D). 
Conversely, overexpression of F/HA-LysRS, followed by RT-qPCR 
analysis showed decreased steady-state and RNA:DNA hybrid–
induced Ifn mRNA levels (Fig. 3E), accompanied by decreased levels of 
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Fig. 2. The Lyslyl tRNA synthetase interacts directly with RNA:DNA hybrids. 
(A) In vitro interaction assay. Three, 10, and 30 pmol of recombinant LysRS, AspRS, 
or p43 were incubated with 20 pmol of BR:D before pull-down using streptavidin 
affinity beads. Input and eluates were analyzed by WB using anti-GST antibody. 
(B) As in (A), except that 3 pmol of recombinant LysRS was incubated with 20 pmol 
of BR:D before pull-down on streptavidin affinity beads. Where indicated, nucleic 
acids were treated with RNaseH before pull-down. Input and eluates were analyzed 
by WB using anti-GST antibody. (C) As in (A), except that 3, 10, and 30 pmol of re-
combinant LysRS, LysRSN, or LysRSC were incubated with 20 pmol of BR:D 
before pull-down using streptavidin affinity beads. Input and eluates were analyzed 
by WB using anti-GST antibody. (D) Three pmol of recombinant LysRS, LysRS∆C, or 
GST were incubated with 20 pmol of BR:D before pull-down using streptavidin 
affinity beads. Where indicated, nucleic acids were treated with RNaseH before 
pull-down. Input and eluates were analyzed by WB using anti-GST antibody. 
(E) Reciprocal immunoprecipitation. F/HA-LysRS was Flag-purified from the cyto-
solic fraction of HeLa cells and used as input material for pull-down using 20 pmol 
of BR:D and streptavidin affinity beads. Where indicated, nucleic acids were treated 
with RNaseH before pull-down. Input and eluates were analyzed by WB using the 
indicated antibodies. (F) Whole-cell extracts from A549 cells stably expressing shLuc 
or shLysRS were used in streptavidin pull-downs using BR:D. Input and eluates 
were analyzed by WB using the indicated antibodies. (G) Whole cell extracts (WCEs) 
from paraformaldehyde (PFA) cross-linked HeLa cells were immunoprecipitated with 
the S9.6 anti–RNA:DNA hybrids antibody or mock immunoglobulin G (IgG) (left). 
Input and eluates were analyzed by WB using an anti-LysRS antibody (right). All 
immunoblots show representative experiments. IP, immunoprecipitation.
 o
n
 M
ay 27, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Guerra et al., Sci. Adv. 2020; 6 : eaax3333     22 May 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 14
A
–
–
+
–
–
+
+
+
–
+
+
+
–
+
+
+
Ifnβ
0
Re
la
tiv
e 
ex
pr
es
sio
n
shLysRS
R:D
Time (hours)
200
400
600
800
1000
– – – – + + + +
0 3 6 12
LysRS
IRF3
pIRF3
GAPDH
0 3 6 12
75
55
55
35
WT-MEF
shLysRS
R:D
3 6 12
shLysRS
R:D
shLysRS
R:D
– – +
– + –
LysRS
IRF3
pIRF3
GAPDH
75
55
55
350.1
1
10
100
1000
*
Ifnβ
Re
la
ti
ve
 e
xp
re
ss
io
n
MEFTrex1 –/–
–
–
+
–
–
+
+
+
*
C
R:D
F/HA-LysRS
10–4
1
10
102
Re
la
tiv
e 
ex
pr
es
si
on
Ifnβ
****
**
–
–
+
–
–
+
+
+
10–3
10–2
10–1
E
75
75
55
55
35
R:D
F/HA-LysRS – –
– +
+ +
– +
LysRS
IRF3
pIRF3
GAPDH
HA
shLysRS
shSting
R:D
Ifnβ
shLysRS
shSting
R:D
– + – +
– – + +
– – – –
–
–
+
+
–
+
–
+
+
+
+
+
LysRS
IRF3
pIRF3
STING
GAPDH
75
55
55
35
35
0
Re
la
ti
ve
 e
xp
re
ss
io
n
0
2
4
8
6
**
**
Re
la
ti
ve
 e
xp
re
ss
io
n
Ifnβ
500
1000
1500
*
*
–
–
–
+
–
–
–
+
–
+
+
–
10
12
–
–
+
+
–
+
–
+
+
+
+
+
2000
2500
J K
L
+
+
H
SV
-1
 t
it
er
 (P
FU
/m
l)
 LysRS +/+ +/– +/+ +/–
H
SV
-2
 t
it
er
 (P
FU
/m
l)
H I
 LysRS
m
RN
A
 le
ve
l (
ar
b
ri
tr
ar
y 
u
n
it
s)
Ifnβ
MNFs LysRS +/+ +/–
G
0 0
2 × 104
0
10–4 104
2 × 10–4
3 × 10–4
4 × 10–4
5 × 10–4
3 × 104
4 × 104
5 × 104
2 × 104
4 × 104
6 × 104
MEFTrex1 –/–
MEFTrex1 –/–
* ****
B
D F
M
shLysRS
R:D
0.1
1
10
1000
100
– +
– –
–
+
+
+
shLysRS
D:D
– +
– –
–
+
+
+
0.1
1
10
1000
100
Re
la
ti
ve
 e
xp
re
ss
io
n
Re
la
ti
ve
 e
xp
re
ss
io
n
0.1
1
10
1000
100
10,000
Re
la
ti
ve
 e
xp
re
ss
io
n
shLysRS
R:R
– +
– –
–
+
+
+
N O
Ifnβ Ifnβ Ifnβ
Fig. 3. The Lysyl tRNA synthetase inhibits RNA:DNA hybrid–induced IFN production. (A) Mean (±SEM) Ifn mRNA levels in shLysRS-expressing versus shLuc-expressing 
WT-MEF transfected or not with R:D for 3, 6, 9, and 12 hours. Representative graph (n = 4). (B) Whole-cell extracts from cells treated as in (A) were analyzed by WB using 
indicated antibodies. (C) Mean (±SEM) Ifn mRNA levels in shLysRS-expressing versus shLuc-expressing MEFTrex1−/− transfected or not with R:D for 6 hours (n = 7). (D) Whole-
cell extracts from cells treated as in (C) were analyzed by WB using indicated antibodies.(E) Mean (±SEM) Ifn mRNA levels in MEFTrex1−/− overexpressing F/HA-LysRS follow-
ing transfection or not with R:D for 6 hours (n = 4). (F) Whole-cell extracts from cells treated as in (E) were analyzed by WB using indicated antibodies. (G) Ifn mRNA levels 
in WT-MNF (mouse neonatal fibroblast) and MNFLysR +/− (cells derived from two independent 1-day-old mice). Different colors indicate different mice. (H and I) WT-MNF and 
MNFLysR +/− were infected with HSV-1 (H) or HSV-2 (I) at multiplicity of infection (MOI) =1, and viral titers were measured 24 hours later. Data represent biological triplicates 
of cells derived from two independent 1-day-old mice. Different colors indicate different mice. (J and K) Mean (±SEM) Ifn mRNA levels in MEFTrex1−/− transduced with shLuc, 
shLysRS, shSting, or shLysRS and shSting prior (J) or after (K) transfection with R:D for 6 hours. Data are expressed relative to shLuc-expressing cells (n = 7). (L) WB analysis 
of whole-cell extracts from experiment performed as in (J) and (K). (M) Ifn mRNA levels in shLuc versus shLysRS-treated MEFTrex1−/− after transfection with R:D for 6 hours. 
(N) Ifn mRNA levels in shLuc versus shLysRS-treated MEFTrex1−/− after transfection with dsDNA (D:D) for 6 hours. (O) Ifn mRNA levels in shLuc versus shLysRS-treated MEFTrex1−/− 
after transfection with dsRNA (R:R) for 6 hours. Results in (M) to (O) are presented as mean Ifn mRNA levels from technical duplicates (representative experiments; n = 3). 
(C, E, I, J, and K) Unpaired t test, *P < 0.05, **P < 0.01, and ****P < 0.0001. All immunoblots show representative experiments. PFU, plaque-forming units.
 o
n
 M
ay 27, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Guerra et al., Sci. Adv. 2020; 6 : eaax3333     22 May 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 14
pIRF3 (Fig.  3F). In further support of the role of LysRS in con-
trolling innate immune responses, primary mouse neonatal fibroblasts 
heterozygous for LysRS (MNFsLysRS+/−; fig. S3E) showed higher basal 
Ifn mRNA levels (Fig. 3G) than their wild-type counterparts 
(MNFsLysRS+/+), together with elevated ISG mRNA levels, including 
Ifit1, Ifit2, Isg15, and Cxcl10 (fig. S3F). Consistent with their ISG 
expression profile, MNFsLysRS+/− poorly support herpes simplex virus 
(HSV) type 1 and 2 replication (Fig. 3, H and I). Thus, our data 
demonstrate that LysRS negatively regulates Ifn expression in a 
model of chronic inflammation and that the absence of LysRS leads 
to the establishment of an antiviral state.
Detection of RNA:DNA hybrids has been previously reported to 
lead to the activation of STING (Fig. 1A) (14). Thus, we next assessed 
whether LysRS-mediated inhibition of Ifn production may rely on 
inhibition of STING activation. To this aim, we knocked down both 
LysRS and Sting in MEFTrex1−/− and measured Ifn mRNA and 
pIRF3 levels by RT-qPCR and WB, respectively. This showed that 
while the absence of LysRS leads to increased Ifn mRNA levels at 
both steady state (Fig. 3J) and upon stimulation with RNA:DNA 
hybrids (Fig. 3K), such increase is lost in the absence of STING 
(Fig. 3, J and K). Consistently, knockdown of LysRS led to increased 
pIRF3 levels (Fig. 3L) that are lost in the double knockdown. We 
confirmed the dependency on STING by knocking down LysRS in 
WT-MEF before transfection with either RNA:DNA hybrids (Fig. 3M) 
and dsDNA (Fig. 3N), which are known to trigger STING-dependent 
signaling, or dsRNA (Fig. 3O), which signals through a different 
pathway (25). The absence of LysRS led to increased Ifn mRNA 
levels in response to RNA:DNA hybrids and dsDNA but not in re-
sponse to dsRNA (Fig. 3, M to O). This is supported by increased 
levels of pIRF3 (fig. S3G). Thus, together, our data demonstrate that 
LysRS delays STING-dependent Ifn expression.
LysRS delays the detection of RNA:DNA hybrids by cGAS
We next questioned the molecular mechanism through which LysRS 
inhibits STING activation. It was previously suggested that cGAS 
may bind to RNA:DNA hybrids because (i) in vitro RNA:DNA hybrids 
can stimulate cGAS-dependent cGAMP production (14) and (ii) 
RNA:DNA-dependent Ifn expression requires cGAS (Fig 1, A and B) 
(14) . Given that we show that LysRS interacts with RNA:DNA hybrids 
(Fig. 2A), we hypothesize that LysRS may inhibit STING activation 
by preventing the association of cGAS with RNA:DNA hybrids. To 
test this hypothesis, we first monitored whether cGAS interacts with 
the RNA:DNA hybrids used in our assays. To this aim, T98G cells, 
which are cGAS deficient, were engineered to stably express FLAG-
HA–tagged cGAS (F/HA-cGAS). The functionality of overexpressed 
cGAS was assesses by monitoring the phosphorylation status of 
IRF3 after transfection with RNA:DNA hybrids and dsDNA (fig. S4A). 
We prepared cytosolic and nuclear extracts (fig. S4B) according to 
(26) from cGAS overexpressing cells, and the cytosolic fraction 
was used for in vitro pull-down experiments using BRNA:DNA hybrids, 
dsBDNA, and ssBDNA immobilized on streptavidin affinity beads. 
Pulled-down material was assessed by WB, showing that cGAS binds 
RNA:DNA hybrids, albeit at lower levels than dsDNA. Next, we 
transfected F/HA-cGAS–expressing T98G cells with BRNA:DNA 
hybrids and dsBDNA before pull-down using streptavidin affinity beads. 
WB analysis of the pulled-down material showed that in cells, cGAS 
interacts both with dsDNA and with RNA:DNA hybrids (Fig. 4B). 
Thus, together, our data demonstrate that cGAS interacts with 
RNA:DNA hybrids.
Having established that both LysRS and cGAS can interact with 
RNA:DNA hybrids, we next wished to investigate the affinity of 
these interactions by calculating the dissociation constant (Kd) of the 
interaction of cGAS or LysRS with RNA:DNA hybrids. To this end, 
we performed in vitro streptavidin pull-down assays using increasing 
amounts of recombinant proteins (fig. S4C) and a fixed amount of 
BRNA:DNA hybrids. Biotin was used as a mock ligand in this assay, 
at the lowest and highest doses of tested proteins. WB analysis 
(Fig. 4C) and quantification of the interaction (Fig. 4D) show a KD 
of ~8.05 nM for cGAS and of ~11.3 nM for LysRS. This indicates 
that LysRS and cGAS have similar affinity for RNA:DNA hybrids 
in vitro. Competition experiments showed that in vitro cGAS can 
compete with LysRS for association to RNA:DNA hybrids (Fig. 4E), 
while LysRS cannot replace cGAS (Fig. 4F).
Knowing that LysRS is an abundant protein and that cGAS is an 
ISG, their relative abundance in cells may be the key in their ability 
to compete. Therefore, to assess whether LysRS can interfere with 
the recruitment of cGAS to RNA:DNA hybrids, we measured intra-
cellular cGAMP levels in the absence of LysRS, at steady state and 
upon RNA:DNA hybrid stimulation (Fig. 4G). This showed that 
knockdown of LysRS leads to higher levels of intracellular cGAMP 
both at steady state and upon stimulation with RNA:DNA hybrids, 
which correlate with higher levels of Ifn mRNA (Fig. 4H) and pIRF3 
(Fig. 4I). Thus, our data indicate that LysRS interferes with cGAMP 
production in response to RNA:DNA hybrids, further implying 
that LysRS likely delays recognition of RNA:DNA hybrids by cGAS.
Ap4A prevents STING-dependent Ifn expression
A role for LysRS in regulation of immune responses was previously 
suggested (15). In particular, under immunological stress, LysRS 
produces Ap4A, an evolutionarily conserved second messenger (27), 
that regulates both gene expression and immune responses (17, 18, 28). 
This led us to question whether the presence of RNA:DNA hybrids 
could be sensed by LysRS as a form of immunological stress and 
consequently stimulate the production of Ap4A, the latter potentially 
contributing to the inhibition of STING-mediated immune responses. 
To test this hypothesis, we transfected WT-MEF with RNA:DNA 
hybrids and measured intracellular Ap4A levels at 0, 3, 6, 9, and 
12 hours after transfection (Fig. 5A). Activation of the cGAS-STING 
pathway was controlled by WB analysis of pIRF3 levels (Fig. 5B). 
This showed that RNA:DNA hybrids stimulate Ap4A production. 
Next, to assess whether RNA:DNA hybrid–dependent Ap4A produc-
tion requires LysRS, we knocked down LysRS before transfection with 
RNA:DNA hybrids for 12 hours (Fig. 5, C and D). LysRS knockdown 
led to the expected decrease of intracellular Ap4A levels. In addi-
tion, the ability of RNA:DNA hybrids to stimulate Ap4A production 
is lost in LysRS knock-down cells, establishing RNA:DNA hybrids 
as trigger for LysRS-dependent Ap4A production.
To investigate whether Ap4A could have an impact on STING- 
dependent inflammation, we treated MEFTrex1−/− with Ap4A for 45, 
90, and 180 min. We observed that Ap4A decreased Ifn mRNA levels 
over the three-hour time course (Fig. 5E). In addition, simultaneously 
treating WT (WT-MEF) and STING knockout MEFs (MEFSting−/−) 
with DMXAA and Ap4A showed that, while cotreatment reduced the 
ability of DMXAA to induce Ifn expression in WT-MEF by half 
(Fig. 5F), no decrease was observed in MEFSting−/− (Fig. 5G). Because it 
is reported that Ap4A has poor capacity to cross the plasma membrane 
(29) and is quickly catabolized in cells (30), we next tested the abili-
ty of JB419 [nonhydrolyzable analog of Ap4A (31)] to modulate Ifn 
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expression. We observed that treatment of MEFTrex1−/− with JB419 
leads to decreased Ifn mRNA levels, comparable to those observed 
upon treatment with Ap4A (Fig. 5H). These experiments suggest that 
Ap4A and its stable JB419 nonhydrolyzable analog can decrease Ifn 
mRNA levels in a model of STING-dependent inflammation. In ad-
dition, Fig. 5G suggests that Ap4A acts through STING, opening the 
possibility that Ap4A may interact with STING. Therefore, we next ques-
tioned whether Ap4A acts through STING to delay the type I IFN 
response by binding to the cGAMP binding pocket of STING. To 
this aim, we used Amber force field (32) and the previously published 
cocrystal of STING with cGAMP [Protein Data Bank (PDB): 4KSY] 
(4) to compare the binding of Ap4A and cGAMP to STING. This 
predicted that cGAMP and Ap4A adopt a similar three-dimension-
al (3D) conformation upon docking to STING (Fig. 5I and fig. S5A). 
Comparison of the interactions between the in silico–docked Ap4A 
to STING (Fig. 5J) to those in the crystal structure of STING and 
cGAMP (fig. S5B) indicates that similar interactions are established. 
Comparison of the potential energies indicates that the Ap4A:ST-
ING complex is more dynamic than the cGAMP:STING complex 
and that the interaction of Ap4A with STING is thermodynami-
cally less stable (table S1). This was confirmed by molecular dy-
namics simulations showing that the Ap4A:STING complex is 
highly unstable compared to cGAMP:STING (fig. S5C).
On the basis of these predictions, we performed in vitro binding 
assays using recombinant GST-tagged C-terminal binding domain 
of mouse STING (GST-STING139–378; fig. S5D) and streptavidin- 
immobilized biotinylated Ap4A. GST and GST-tagged mouse Histi-
dine triad nucleotide-binding protein 1 (Hint1) (fig. S5D), reported 
to bind Ap4A (33), were included as negative and positive controls, 
respectively. We observed that, as predicted in silico, STING139–378 
interacts with Ap4A (Fig. 5K). Also in agreement with in silico pre-
dictions (table S1), competition experiments using unlabeled Ap4A, 
cGAMP, or DMXAA as competitors showed that binding of bioti-
nylated Ap4A to STING can be easily displaced (Fig. 5L). The JB419 
nonhydrolyzable analog of Ap4A also competed for the binding of 
STING to Ap4A (Fig. 5L), further suggesting that JB419 also inter-
acts with STING. Thus, these data indicate that Ap4A can bind to 
STING. Our observations also confirm the in silico predictions that Ap4A 
and cGAMP share the same binding pocket on STING and that the 
binding of Ap4A to STING is less stable as compared to that of cGAMP. 
We therefore propose a model where LysRS and Ap4A regulate the 
activation of STING by two complementary mechanisms. First, LysRS 
recognizes cytosolic RNA:DNA hybrids, delaying their detection 
by cGAS. Second, binding of LysRS to RNA:DNA hybrids stim-
ulates the production of Ap4A, which delays the binding of cGAMP 
to STING, resulting in delayed IFN response (Fig. 5M, left). In the 
absence of LysRS, cGAS recognizes RNA:DNA hybrids leading to a 
higher cGAMP production and subsequent type I IFN response 
(Fig. 5M, right).
LysRS-mediated negative regulation of Ifn expression  
is conserved in zebrafish
Last, we wished to challenge our finding in vivo in zebrafish embryos, 
taking advantage of the close evolutionary resemblance of their in-
nate antiviral pathways to that of humans (34). We first verified that 
recombinant zebrafish LysRS (zLysRS) interacts with RNA:DNA 
hybrids in vitro (Fig. 6A). We then performed whole-body knock-
down of the unique zebrafish ortholog of LysRS (zLysRS) by injecting 
wild-type one-cell zebrafish embryos with a splice-blocking morpholino 
targeting zlysrs (Fig. 6B) or with a control morpholino. Microscopy 
analysis of fish morphology showed no developmental defect (Fig. 6C). 
Quantification of the expression levels of type I IFN (ifnφ1) and the 
IFN-response gene isg15 at 72 hours after injection showed that 
knocking down lysrs led to a global up-regulation of the IFN response 
(Fig. 6D). This establishes that negative regulation of type I IFN by 
LysRS is conserved in fish and mammals.
DISCUSSION
In summary, we show that RNA:DNA hybrids are bona fide ligands 
of cGAS and that LysRS represses RNA:DNA hybrid–dependent 
cGAS-STING activation through two complementary mechanisms. 
First, LysRS interacts with RNA:DNA hybrids, preventing, or delay-
ing, their recognition by cGAS. Consistently, knocking down LysRS 
leads to enhanced cGAMP production, attesting to increased cGAS 
activation. This infers that in the absence of LysRS the bioavailability 
of RNA:DNA hybrids for recognition by cGAS is enhanced. Con-
sidering that cGAS is an ISG and that LysRS is highly expressed in 
cells, their relative abundance is likely to be a key determinant of 
STING activation. In pathological situations where acute nucleic 
acid–induced STING stimulation occurs, such as upon chemotherapy 
or radiotherapy regimens or viral infections (35), it is likely that 
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masking of RNA:DNA hybrids by LysRS is critical. Second, we 
identify here that simulation with RNA:DNA hybrids leads to 
LysRS-dependent Ap4A production that, in turn, delays the activation 
of type I IFN responses by binding to the cGAMP binding pocket of 
STING, confirming its signaling function in mammalian cells 
(17, 18, 28).
LysRS-dependent inhibition of STING is likely complementary 
to existing cellular processes that regulate cytosolic levels of nucleic 
acids to avoid unwanted triggering of the cGAS-STING pathway (7). 
Enzymes such as deoxyribonuclease II (DNase II), TREX 1, RNaseH 
1, or RNaseH 2 are in charge of degrading cytosolic nucleic acids, 
preventing their detection. Thus, at resting state, despite the poten-
tial generation of RNA:DNA hybrids through processes such as 
transcription-replication collision or immunoglobulin class switching 
(11), it is likely that LysRS is mostly engaged in translation. Hence, 
in the absence of such nucleases, the LysRS-Ap4A pathway may play 
a pivotal role. For example, it is reported that the absence of RNaseH2 
leads to up-regulation of STING-dependent type I IFN responses 
through the appearance of dsDNA species containing ribonucleotides 
that induce DNA damage rather than through an increase of total 
RNA:DNA hybrids (36). While it can be expected that, in this model, 
LysRS would not have its inhibitory effect, due to the lack of 
RNA:DNA hybrids, it would be important to assess the impact of 
treatment with Ap4A or JB419. In addition, it has been shown that 
members of the MSC can interfere with retroviral life cycles. In par-
ticular, LysRS interferes with the HIV-1 replication cycle (15) and 
that HIV-1 infection promotes nuclear translocation of LysRS (37), 
a process that may lead to the production of Ap4A (18), favoring the 
viral life cycle by decreasing the antiviral response. It would be 
therefore important to test whether LysRS is able to bind HIV-1–
derived RNA:DNA hybrids, whether this leads to Ap4A production, 
and the impact of the latter on the viral life cycle.
While our work reveals that the LysRS-Ap4A axis is a key path-
way involved in physiological regulation of STING activation, it also 
raises questions regarding the involvement of the MSC in regulating 
the innate immune responses. Other members of the MSC, such as 
bifunctional glutamate/proline-tRNA ligase (EPRS) (38), have already 
been shown to play roles in the regulation of immune responses. 
Thus, it would be important to examine whether knocking down addi-
tional members of the MSC, together with LysRS, can enhance the 
effect of LysRS on the cGAS-STING pathway. In addition, we also 
show that LysRS-mediated inhibition of type I IFN response is a con-
served mechanism in mammals and fish. However, it is likely that 
the overall involved molecular mechanisms differ. While it has been 
described that in vitro, the zebrafish orthologs of cGAS can produce 
cGAMP (39), it has been previously reported that cGAS is dispens-
able for innate immune detection, to the contrary of probable 
ATP- dependent RNA helicase DDX41 and ATP-dependent RNA he-
licase A (DHX9), in zebrafish (40). It would therefore be important 
to test whether LysRS-mediated inhibition of IFN responses may 
be mediated by sequestration of RNA:DNA hybrids from other sen-
sors than cGAS.
Last, our data also show that the JB419 cell-permeant nonhydro-
lyzable analog of Ap4A (31) antagonizes STING to levels similar to 
those observed for Ap4A. Thus, this compound bears the potential 
for translation to the clinic and opens the way to the design of derived 
compounds with higher affinity for STING or increased retention 
time in the cGAMP-binding pocket. While such compounds would 
have to be carefully assessed for side effects and cytotoxicity before 
testing in animal models of chronic inflammation, our study pro-
vides basis for the design of a novel class of pharmaceutical inhibitors 
of STING. In addition, activating endogenous LysRS to produce Ap4A 
may also be a relevant approach to study the effect of long-term 
exposure to these compounds on global immune responses. Our work 
thus warrants further studies to better characterize the role of the 
LysRS-Ap4A axis in human pathologies where inflammatory responses 
are reported.
MATERIALS AND METHODS
Study design
The present study aimed at identifying the molecular mechanisms 
governing regulation of STING activation. Experiments performed 
in vitro, in cells, and in vivo were carefully controlled. In vitro ex-
periments performed using recombinant proteins or cell lysates were 
performed independently using different protein preparations. 
Experiments performed in cells were performed in technical dupli-
cates or triplicates, and biological repetitions are indicated in the 
figure legends. In vivo experiments in zebrafish were repeated twice 
on pools of three individual larvae. Morpholino injections were 
blinded. No outlier was excluded in the course of the analyses.
Cells and cell cultures
293T, A549, HeLa, HeLa-S3, WT-MEF, MEFSting−/−, MEFcGas−/−, 
MEFTrex1−/−, T98G, and T98GF/H-cGAS were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamine. 
T98G overexpressing F/HA-cGAS were generated by transducing 
parental T98G with viral particles produced by using the pOZ-F/
HAcGAS construct and selected with puromycin. Cells were maintained 
in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 
and 1% glutamine. A549 were obtained from S. Goodborn. WT-MEF, 
MEFSting−/−, and MEFcGas−/− were a gift of S. R. Paludan, MEFTrex1−/− 
were obtained from J. Rehwinkel, and parental T98G were obtained 
from C. Goujon.
Mouse neonatal fibroblast
MNFs were purified as described by the Krishma Halai laboratory. 
Briefly, skin was isolated from newborns at day 1, incubated in 
Krebs-Ringer Hepes (KRH) buffer containing 10 mM Hepes and 1% 
penicillin/streptomycin and minced in pieces with a scalpel before 
digestion in KRH/ATB buffer supplemented with collagenase (1 mg/ml) 
at 37°C. After centrifugation at 1000 rpm for 5 min, the supernatant 
was discarded, and the isolated cells put in culture in DMEM, 20% 
FBS, and 1% penicillin/streptomycin.
Plasmids
shRNAs targeting LysRS and STING were cloned into the pSUPERIOR.
retro.puro vector from Oligoengine, according to the manufacturer’s 
instructions. N-terminally Flag- and HA-tagged codon-optimized 
mouse LysRS (MWG Eurofins) was cloned into the pOZ retroviral 
vector. For bacterial expression of recombinant proteins, the human 
LysRS gene was amplified by PCR from complementary DNA 
(cDNA) of HeLa cells. The cDNA and codon-optimized human cGAS 
(MWG Eurofins) were cloned into the pGEX-4T1 plasmid. Codon- 
optimized mouse LysRS was cloned into the pGEX-4T1 plasmid. 
Danio rerio LysRS (zLysRS) was amplified by PCR from the cDNA 
of zebrafish larvae and cloned in pGEX-4T1.
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Viral particle production and infection
shRNA-expressing retroviral particles were produced by cotransfection 
of 2 × 106 293T cells with 5 g of shRNA-containing pSUPERIOR, 
2.5 g of murine leukemia virus (MLV) GagPol, and 2.5 g of A-MLV 
envelope, using the standard calcium phosphate transfection protocol. 
Retroviral particles containing the transgene encoding Flag- and 
HA-tagged LysRS (F/HA-LysRS) were produced following the same 
procedure except that cells were cotransfected with 5 g of pOZ-F/
HALysRS, 2.5 g of MLV GagPol, and 2.5 g of A-MLV envelope. 
Viral particles were harvested 48  hours after transfection, filtered 
with 0.45 M filters, and used for transduction.
For knockdown of LysRS, 105 cells were seeded 24 hours before 
transduction. Medium was replaced 10 hours after transduction, 
and transfection was performed 72 hours later. A similar procedure 
was used for knockdown of LysRS and STING, except that retro-
viral particles containing shRNAs targeting LysRS and STING were 
added at the same time. For expression of F/HA-LysRS, 5 × 105 cells 
were seeded 24 hours before transduction. Twenty-four hours later, 
viral particles were added, and medium was replaced after 
10 hours. RNA:DNA hybrids were transfected 96 hours later.
HSV plaque assay
MNFs were seed at a density of 0.5 to 1 × 105 cells per well in a 
24-well plate (Nunc) in 500 l of DMEM + 1% FBS 24 hours before 
infection with HSV-1 KOS or HSV-2 333 at multiplicity of infection 
(MOI) of 0.1. Supernatants were harvested 24 hours later, and virus 
yield was quantified using the plaque titration assay on Vero cells.
Protein purification
Recombinant GST-HINT, GST-LysRS, GST-cGAS, GST-STING 
(amino acids 139 to 378), and GST-ZfLysRS were produced in 
Escherichia coli BL21 cells. E. coli transformed with GST or GST expression 
constructs were grown in LB medium at 37°C to an absorbance at 
600 nm of 0.6 before induction with 0.25 mM isopropyl--d-1-thioga-
lactopytanoside overnight at 16°C. Bacteria were harvested by cen-
trifugation, resuspended in TETN-100 buffer [50 mM tris-HCl (pH 8), 
100 mM NaCl, 1 mM EDTA, and 0.1% Triton X-100, supplemented 
with lysozyme (2 mg/ml; Sigma), 10 mM -mercaptoethanol, and 
0.5 mM phenylmethylsulfonyl fluoride (PMSF)], and incubated on 
ice for 30 min. Salt and detergent concentrations were increased, 
respectively, to 400 mM and 0.5% before sonication. Lysates were 
resuspended in TETN-400 buffer [50 mM tris-HCl (pH 8), 400 mM 
NaCl, 1 mM EDTA, and 0.5% Triton X-100, supplemented with 
10 mM - mercaptoethanol and 0.5 mM PMSF] and were clarified by 
centrifugation at 13,000 rpm for 30 min at 4°C before incubation 
with the appropriate volume of glutathione-Sepharose beads for 
4 hours at 4°C. Sepharose beads were washed three times with ice-cold 
TETN-400, and recombinant proteins were eluted with elution buffer 
[150 mM NaCl and 50 mM tris-HCl (pH 8)] supplemented with 30 mM 
reduced l-glutathione. Eluates were quantified by Coomassie staining.
Nuclear cytoplasmic fractionation
T98GF/H-cGAS cells were fractionated according to Gentili et al. (26) 
Briefly, cells were harvested and cell pellet was washed once in 400 l of 
cold cytoplasmic lysis (CL) buffer [10 mM Hepes (pH 7.9), 10 mM 
KCl, and 1.5 mM MgCl2] in the presence of 0.5 mM PMSF and cen-
trifuged at 300g for 4 min. The supernatant was discarded, and cell 
pellet was lysed by adding three cell pellet volumes of cold CL for 
10 min on ice, with gentle flicking. Cytosolic extract was obtained 
by adding 0.625% final of NP-40 for an additional of 5 min on ice, 
with gentle flicking. Nuclei were pelleted at 16,000g for 5 min, and 
cytosolic extracts were collected in a fresh tube. Nuclei were then 
lysed by adding three cell pellet volumes of cold nuclear lysis buffer 
[420 mM NaCl, 20 mM Hepes (pH 7.9), 1.5 mM MgCl2, 0.2 mM 
EDTA, 25% glycerol, and 0.5 mM PMSF] for 15 min on ice, with 
gentle flicking. Nuclear lysates were vortexed and sonicated for 20 min 
at 4°C in a Bioruptor ultrasonic bath. Nuclear lysates were cleared 
by centrifugation at 16000g for 5 min.
Biotinylated nucleic acid pull-down using  
recombinant protein
In vitro interaction between RNA:DNA hybrids and recombinant 
proteins was performed using Dynabeads M280. Beads were blocked 
overnight in blocking buffer [20 mM Hepes (pH 7.9), 15% glycerol, 
0.05% NP-40, and 50 mM NaCl, supplemented with 2 mM dithiothreitol 
(DTT), 100 mM NaCl, and bovine serum albumin (BSA; 10 mg/ml)]. 
After three washes in 1× wash buffer [5 mM tris-HCl (pH 7.5), 1 mM 
EDTA, and 1 M NaCl], M280 beads were coupled to nucleic acids 
according to the manufacturer’s instructions. Briefly, beads were 
incubated in 30 l of 2× wash buffer [10 mM tris-HCl (pH 7.5), 
2 mM EDTA, and 2 M NaCl] containing 20 pmol of BRNA:DNA 
hybrids at 25°C for 15 min. Protein binding was performed at 37°C 
for 30 min with increasing amounts of recombinant proteins in 20 mM 
Hepes (pH 7.9), 15% glycerol, 0.05% NP-40, and 150 mM NaCl, 
supplemented with 2 mM DTT, 2 mM PMSF, and RNase inhibitor. 
When indicated, hybrids were treated with 30 U of RNaseH (Ambion) 
in RNaseH buffer [50 mM tris-HCl (pH 8), BSA (50 ng/ml), 1 mM 
DTT, and 4 mM MgCl2] for 1 hour at 30°C, before binding to the 
beads. After three washes, bound material was eluted in 30 l of 
Laemmli buffer. Pull-down in competition between hcGAS and 
hLysRS was performed as described above except that the two 
proteins were added at the same time to the beads coupled to the 
BRNA:DNA hybrids.
Biotinylated nucleic acid pull-down using cell extracts
Interaction of endogenous protein and transfected biotinylated 
nucleic acids was tested by transfecting HeLa cells with nucleic acids 
(2 g/ml) using JetPrime according to the manufacturer’s protocol. 
Six hours after transfection, cells were harvested and lysed in 
TENTG-150 [20 mM tris-HCl (pH 7.4), 0.5 mM EDTA, 150 mM 
NaCl, 10 mM KCl, 0.5% Triton X-100, 1.5 mM MgCl2, and 10% glycerol, 
supplemented with 10 mM -mercaptoethanol and 0.5 mM PMSF] 
on ice for 30 min. Lysates were centrifuged at 13,000 rpm for 30 min 
at 4°C. Equal amounts of whole-cell lysates were incubated for 
3 hours at 4°C on a wheel with 3 g (30 l) Dynabeads M280 blocked 
overnight at 4°C as described above. After three washes in 20 mM 
tris-HCl (pH 7.4), 0.5 mM EDTA, 0.05% Triton, 0.1% Tween, 150 mM 
NaCl, 10% glycerol, and 5 mM MgCl2, bound material was eluted in 
Laemmli buffer.
In vitro biotinylated nucleic acid pull-down
Pull-down was carried out using 3 g (30 l) of Dynabeads M280 per 
condition. Beads were blocked overnight as described above. After 
three washes in 1× wash buffer, 100 pmol of nucleic acid was coupled 
to M280 beads according to the manufacturer’s instructions before 
equilibration in dialysis buffer [20 mM tris-HCl (pH 7.4), 0.5 mM 
EDTA, 150 mM NaCl, 10% glycerol, and 1.5 mM MgCl2]. Cytosolic 
extracts from HeLa S3 cells, prepared using the Dignam protocol, were 
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diluted in dialysis buffer supplemented with 2% Tween, 1% Triton, 
10 mM -mercaptoethanol, and 0.5 mM PMSF and centrifuged at 
13,000 rpm for 30 min at 4°C. One milliliter of diluted lysate was 
added to the beads and incubated at 4°C on a rocker for 4 hours in 
low-binding tubes (Axygen). Three consecutive washes were per-
formed in 20 mM tris-HCl (pH 7.4), 0.5 mM EDTA, 0.05% Triton, 
0.1% Tween, 150 mM NaCl, 10% glycerol, and 5 mM MgCl2. Tubes 
were changed at first and last washes. Bound material was eluted 
in 30 l of Laemmli buffer.
Pull-down using biotinylated Ap4A  
and recombinant proteins
In vitro interaction between STING and biotinylated Ap4A was tested 
using Dynabeads M280, blocked as described above. Ten micromolar 
of biotinylated Ap4A (BioLog) or biotin was bound to the beads at 
25°C for 30 min in 2× wash buffer. Thirty, 50, or 100 g of recom-
binant proteins (mSTING, mHINT, and GST) was incubated with 
the beads for 1 hour at 4°C on the wheel in a final volume of 200 l 
in 150 mM NaCl, 50 mM tris-HCl (pH 8.0), 10 mM MgCl2, BSA 
(0.1 g/l), 10 mM -mercaptoethanol, and 0.5 mM PMSF. Com-
petition was performed after protein binding using a 10-fold excess 
of the competitor (DMXAA, 2′3′-cGAMP, Ap4A, or JB419) for 1 hour 
at 4°C on wheel in a final volume of 200 l in the buffer described 
above. After three washes in 150 mM NaCl, 50 mM tris-HCl (pH 8.0), 
10 mM MgCl2, 0.1% Tween, BSA (0.1 g/l), 10 mM -mercaptoethanol, 
and 0.5 mM PMSF, bound material was eluted in 30 l of Laemmli 
buffer.
S9.6 immunoprecipitation
Endogenous RNA:DNA hybrids were immunoprecipitated using the 
S9.6 antibody. Briefly, HeLa cells were crosslinked with 1% para-
formaldehyde (PFA) for 20 min at room temperature. PFA was 
quenched by incubation with 125 mM glycine for 5 min at room 
temperature. Cells were harvested and lysed in TENTG-150 on ice 
for 30 min. Lysates were centrifuged at 13,000 rpm at 4°C for 30 min. 
The soluble fraction was precleared for 20 min at 4°C with 15 l of 
agarose protein G beads, followed by incubation overnight at 4°C 
with 30 l of agarose protein G beads coupled to 10 g/ml of either 
irrelevant mouse immunoglobulin G (IgG) or S9.6 antibody. Beads 
were washed five times in TENTG-150 buffer, and immunoprecipitated 
material was eluted in Laemmli buffer.
RNA extraction and RT-qPCR
RNA was extracted using TRIzol (Invitrogen) and treated with 
TURBO DNase (Ambion) according to manufacturer’s protocols. 
Reverse transcription (SuperScript IV reverse transcriptase, Invitrogen) 
and qPCR using specific primers were performed using SYBR 
Green Master Mix (Takara) and LightCycler 480 cycler (Roche). 
mRNA levels were normalized to Gapdh mRNA levels except in 
zebrafish experiments where mRNA levels were normalized to 
zebrafish actin (zactin).
Whole-cell extract preparation and immunoblot
Cells were either lysed in 3 packed cell volume (PCV) of radio-
immunoprecipitation assay buffer [150 mM NaCl, 50 mM tris-HCl 
(pH 8), 0.5% sodium deoxycholate, 0.1% SDS, and 1% NP-40] sup-
plemented with 0.5 mM PMSF for 15 min at 4°C or 5 PCV of 
TENTG-150 for 30 min at 4°C. Lysates were centrifuged 30 min 
at 13,000 rpm, and supernatants were collected for immunoblot. 
For phosphorylated protein analysis, buffer was supplemented with 
PhosphoSTOP (Roche) before whole-cell extraction. Protein quan-
tification was performed using Bradford assay. Samples were re-
solved on SDS-PAGE, and proteins were transferred onto nitro-
cellulose membranes. Primary antibodies used include anti-phospho 
IRF3 (1:500; Cell Signaling 4D4G; 1:500; Abcam Ab76493), anti- IRF3 
(1:1000; Cell Signaling D6I4C), anti-phospho TBK1 (1:1000; Cell 
Signaling D52C2), anti-TBK1 (1:1000; Cell Signaling D1B4), anti- 
STING (1:1000; Cell Signaling D2P2F), anti-HA (1:10000; Roche), 
anti–glyceraldehyde-phosphate dehydrogenase (GAPDH; 1:5000; 
Proteintech Europe 800004-1-Ig), anti-AMP1 (1:1000; Bethyl 
Laboratories A304896A-M), anti-DARS (1:1000; Bethyl Labo-
ratories A304799A-M), anti-human LysRS (1:1000; Bethyl Labo-
ratories A300630A-M), anti-mouse LysRS (1:2000; Proteintech 
Europe 14951-1AP), anti-GST (1:10000; Bethyl Laboratories 
A190122A), anti PARP-1 (1:500; Santa Cruz Biotechnology F-2 
sc8007), anti-tubulin (1:2000; Proteintech Europe 66031-1-Ig), 
anti–TREX-1 (1:250; Santa Cruz Biotechnology C-11 sc133112), 
and anti-cGAS mouse specific (1:1000; Cell Signaling D3080). 
The S9.6 antibody was a gift from S. Leppla. All secondary anti-
bodies (Cell Signaling) were used at 1:2000 dilution. Signal was 
visualized with SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Fisher Scientific), and images were acquired on a 
ChemiDoc (Bio-Rad).
Morpholino knock-down experiments
Eggs of wild-type AB zebrafish (one-cell stage) were microinjected 
with 4 ng of the KARS- specific antisense morpholino (MO3i3, TC-
CATATTCGCTACTCATCGTACA) or with a control morpholino 
(MOctl, GAAAGCATGGCATCTGGATCATCGA). The KARS- 
specific MO targets the splice donor site between exon 3 and intron 4. 
Efficiency of knockdown was assessed by RT-qPCR with splice- 
sensitive primers [TGGACCCCAATCAATACTTCAAG (forward) 
and GGTCTCCAGGCTGAAGGTGGTTAT (reverse)]. Embryos 
then developed with no obvious morphological defects at 28°C. At 
72 hours after injection, embryos were collected for gene expression 
analysis by RT-qPCR.
Molecular modeling
Molecular docking of Ap4A on STING was performed using ZDOCK 
version 3.0 using the STING crystal structure (PDB: 4KSY). RDOCK 
was used to refine and quickly evaluate the results obtained by 
ZDOCK. Energy minimization was performed to remove the geo-
metrical strain from the top-ranking poses of Ap4A during the dock-
ing experiments. Top hit complexes of Ap4A and STING were 
subjected to extensive energy minimization run using the Amber99 
force field as it is implemented into Gromacs, version 4.5.5, via the 
Gromita graphical interface, version 1.07. An implicit generalized 
born solvation was chosen at this stage, in an attempt to speed up 
the energy minimization process.
The interaction space and binding potential of each docking 
conformation were further explored by subjecting the molecular 
complexes to unrestrained molecular dynamics simulations using 
the Gromacs suite, version 4.5.5. Molecular dynamics took place in 
a periodic environment, which was subsequently solvated with 
sphingosylphosphoryl choline water using the truncated octahedron 
box extending to 7 Å from each molecule. Partial charges were ap-
plied, and the molecular systems were neutralized with counter ions 
as required. The temperature was set to 300 K, and the step size was 
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set to 2 fs. The total run of each molecular complex was 100 ns, using 
the NVT ensemble in a canonical environment. NVT stands for 
number of atoms, volume, and temperature that remain constant 
throughout the calculation. The results of the molecular dynamics 
simulations were collected into a molecular trajectory database for 
further analysis.
Determination of intracellular Ap4A levels in MEF and HeLa
Cellular nucleotide extraction and Ap4A determination were per-
formed using a sensitive luminescence-based assay. Briefly, nucleotides 
were extracted from cells by adding 5 ml of ice-cold trichloroacetic 
acid and subsequent neutralization with an equal volume of 0.6 M 
tri-octylamine in 1,1,2-trichlorotrifluoroethane. Following cen-
trifugation at 500g for 5 min, the top aqueous layer was removed, 
and 10 U of thermo-sensitive alkaline phosphatase (Thermo Fisher 
Scientific) was added to degrade adenosine triphosphate (ATP). 
Remaining nucleotides were concentrated using DEAE-Sephacel 
beads. Following mixing and centrifugation at 12,000g for 1 min, 
beads were washed with water. Nucleotides bound to DEAE-Sephacel 
were eluted twice with 1 M triethylammonium bicarbonate (pH 8.5), 
and eluates were vacuum-dried. Nucleotides from the two eluates 
were combined and dissolved in 120 l of Ap4A assay buffer [25 mM 
Hepes-NaOH (pH 7.8) and 5 mM magnesium acetate]. To remove 
any remaining ATP, a further 10 U of alkaline phosphatase was 
added, incubated at 37°C, and subsequently incubated at 95°C 
to denature alkaline phosphatase. Ap4A levels in 10 l of sample 
were determined by adding 50 l of Bactiter GLO (Promega). Back-
ground ATP levels were first measured on a Berthold Lumat 9507, 
and once stabilized, recombinant Ap4A hydrolase was added to 
cleave Ap4A (ATP + AMP), and levels of ATP were measured by 
the increase in luminescence. Levels of Ap4A in samples were de-
termined by comparison to standards and expressed as pmol per 
106 cells.
cGAMP ELISA
cGAMP enzyme-linked immunosorbent assay (ELISA) was per-
formed according to the manufacturer’s protocol using the Cayman 
Chemical 2′3′-cGAMP ELISA Kit (Bertin Bioreagents). MEFTrex−/− 
were seeded at 3 × 106 in 150-cm2 plates 24 hours before trans-
duction. Forty-eight hours later, cells were seeded at 3 × 106, and 
24 hours later, cells were transfected with RNA:DNA hybrids 
(2 µg/ml). For cGAMP quantification, cells were harvested, counted, 
washed in phosphate-buffered saline (PBS), pelleted, and frozen 
in 500 l of 80% MeOH/H2O (80/20, v/v) at −80°C until extraction. 
Samples were thawed and subjected to five freeze/thaw cycle in 
liquid nitrogen. Lysates were centrifuged at 16,000 rcf at 4°C for 
20 min. The recovered supernatants were subjected to speed vac-
uum drying in SAVAN 110 SpeedVac Concentrator at 65°C for 
2 hours. The pellets were resuspended in 50 l of RNase/DNase- 
free water.
Radiolabeling
For radiolabeling experiments, HeLa cells were lysed in TENTG- 
150 buffer, and DNA was extracted with phenol/chloroform/isoam-
yl (pH 8) (12/12/1). DNA was subsequently dephosphorylated 
using Shrimp Alkaline Phosphatase (rSAP) New England Biolabs 
(NEB) before labeling with 32P ATP for 30 min at 37°C using the 
T4 polynucleotide kinase (NEB). Subsequent RNaseH treatment 
was performed with 10, 20, or 40 U following the manufacturer’s 
protocol. Unbound radiolabeled nucleotides were removed using 
Illustra Microspin G-50 Columns before resolution on 5% acrylamide, 
0.5% tris borate ethylamide gel, and autoradiography. Images were 
acquired using Thyphoon FLA 7000.
Cell treatment and transfection
Cells were transfected with JetPrime transfection reagent (Polyplus) 
at 1:2 ratio with various nucleic acids at 2 g/ml. DMXAA (Invivogen) 
was used at 200 M in Opti-MEM (Gibco). Ap4A (Sigma-Aldrich) or 
JB419 was used at 500 M in Opti-MEM.
Immunofluorescence and microscopy analysis
WT-MEF were plated 24 hours before transfection with Cyanin3- 
labeled RNA:DNA hybrids (2 g/ml) in Opti-MEM using the Jet-
Prime reagent, according to the manufacturer’s instructions. Two 
hours after transfection, cells were detached with 0.5 mM EDTA 
in PBS and plated on fibronectin-treated coverslips. Four hours 
later, cells were fixed with 4% PFA in PBS, and permeabilization 
was performed with 0.1% Triton X-100 in PBS for 5 min at room 
temperature (RT). After blocking in PBS containing 0.1% Tween 
(PBS-T) and 5% BSA for 30 min at RT, cells were incubated over-
night with the S9.6 antibody at 1/200 dilution in PBS-T, 5% BSA.
RNaseH treatment before primary antibody incubation was per-
formed, when indicated, with 60 U of RNaseH (Ambion) in 
RNaseH buffer in a humid chamber overnight at 30°C. Secondary 
antibody incubation was performed for 1 hour at RT. Cytoskeleton 
was stained with Actin Green 488 ReadyProbes reagent (Molecular 
Probes by Life Technologies), and the nucleus with 4′,6-diamidino- 
2-phenylindole. Vectashield reagent was used to mount the cover-
slips. Z-stacks were acquired by a Apotome Z2 microscope by 
Zeiss with ZEN (blue edition) software, and images were processed 
with Fiji.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 7. 
Unpaired or one-column t test was performed as indicated in figure 
legends.
Compounds (PubChem CID)
DMXAA (Vadimezan): 123964
Ap4A (Diadenosine tetraphosphate): 21706
2′3′ cGAMP (cyclic guanosine monophosphate-adenosine mono-
phosphate): 135564529
Oligonucleotide sequences
mIFN fw 5′-CTGCGTTCCTGCTGTGCT TCTCCA-3′
mIFN rv 5′-TTCTCCGTCATCTCCATA GGGATC-3′
mSTING fw 5′-TTGGGTACTTGGGGTTGATCTT-3′
mSTING rv 5′-GCACCACTGAGCATGTT GTTATG-3′
mLysRS fw 5′-GTACTGCCCTGGAATAC GGG-3′
mLysRS rv 5′-TTTCAGTGGTCGCTGCAG TT-3′
mGAPDH fw 5′-TTCACCACCATGGAGAAGGC-3′
mGAPDH rv 5′-GGCATCGACTGTGGTCATGA-3′
zfACTIN fw 5′ CGAGCTGTCTTCCCATCCA 3′
zfACTIN rv 5′-TCACCAACGTAGCTGTCTTTCTG-3′
zfIFN fw 5′-GAATGGCTTGGCCGATACAGGATA-3′
zfIFN rv 5′-TCCTCCACCTTTGACTTGTCCATC-3′
zfLysRS fw P2 5′-TGGACCCCAATCAATACTTCAAG-3′
zfLysRS rv P2 5′-GGTCTCCAGGCTGAAGGTGGTTAT 3′
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Morpholino sequences
MO3i3 5′-TCCATATTCGCTACTCATCGTACAT-3′
Control MO 5′-TACCAAAAGCTCTCTTATCGAGGGA-3′
Oligo sequences for annealing
RNA 2 or BRNA 2 were annealed with RNA 5 to generate non bio-
tinylated or biotinylated dsRNA; RNA 2 or BRNA 2 were annealed 
with DNA 9 to generate nonbiotinylated or biotinylated RNA: 
DNA hybrids; DNA 9 or BDNA 9 were annealed with DNA 6 
to obtain nonbiotinylated or biotinylated dsDNA. Annealing was 
performed in a MasterCycler nexus gradient (Eppendorf) in an-
nealing buffer [60 mM NaCl, 5 mM tris-HCl (pH 7.5), and 0.2 mM 
EDTA] using the following program: 4 min at 95°, 85°, 82°, 
80°, 78°, 75°, and 72°C, followed by 10 min at 70°C and slow cool-
ing down to 10°C over a period of 2 hours. The quality of annealed 
material was controlled by running 500 ng of annealed material on 
a 10% nondenaturing acrylamide gel using ssRNA and ssDNA as 
controls.
RNA 2: UUU CAA UUC CUU UUA GGA UUA AUC UUG 
AAG AUA GAG UUA A
RNA 5: UUA ACU CUA UCU UCA AGA UUA AUC CUA 
AAA GGA AUU GAA A
DNA 9: TTA ACT CTA TCT TCA AGA TTA ATC CTA AAA 
GGA ATT GAA A
DNA 6: TTT CAA TTC CTT TTA GGA TTA ATC TTG AAG 
ATA GAG TTA A
BRNA 2: BIO- UUU CAA UUC CUU UUA GGA UUA AUC 
UUG AAG AUA GAG UUA A
BDNA 9: BIO- TTA ACT CTA TCT TCA AGA TTA ATC CTA 
AAA GGA ATT GAA A
shRNA sequences
shSTING fw (mouse)
5′-GATCCCCTGATTCTACTATCGTCTTATTCAAGAGA-
TAAGACGATAGTAGAATCATTTTTC-3′
shSTING rv (mouse)
5′-TCGAGAAAAA TGATTCTACTATCGTCTT ATCTCTT-
GAATAAGACGA TAGTAGAATCAGGG-3′
shLysRS fw (mouse) 1
5′-GATCCCCGAATCAGCATGGTAGAAGATTCAA-
GAGATCTTCTACCATGCTGATTCTTTTTC-3′
shLysRS rv (mouse) 1
5′-TCGAGAAAAAGAATCAGCATGGTAGAAGATCTCTT-
GAATCTTCTACCATGCTGATTCGGG-3′
shLysRS fw (mouse) 2
5′-GATCCCCGAAATTTATCGTCCGCTCTTTCAAGAGAA-
GAGCGGACGATAAATTTCTTTTTC-3′
shLysRS rv (mouse) 2
5′-TCGAGAAAAAGAAATTTATCGTCCGCTCTTCTCTT-
GAAAGAGCGGACGATAAATTTCGGG-3′.
shLysRS fw (mouse) 3
5′-GATCCCCGCCTTTCATCACCTATCACTTCAAGA-
GAGTGATAGGTGATGAAAGGCTTTTTC-3′
shLysRS rv (mouse) 3
5′-TCGAGAAAAAGCCTTTCATCACCTATCACTCTCTT-
GAAGTGATAGGTGATGAAAGGCGGG-3′
shLysRS fw (human)
5′-GATCCCCCAAGGTATCGCCAGAGATATTCAAGAGA-
TATCTCTGGCGATACCTTGTTTTTC-3′
shLysRS rv (human)
5′-TCGAGAAAAACAAGGTATCGCCAGAGATATCTCTT-
GAATATCTCTGGCGATACCTTGGGG 3′
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/21/eaax3333/DC1
View/request a protocol for this paper from Bio-protocol.
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